Primers and Probes for the Amplification and Detection of HIV GAG, REV and NEF Polynucleotides
AssigneeArgos Therapeutics, Inc.
InventorsIrina Tcherepanova, Aijing Starr, Brad Lackford
Life of this patent
Estimating the term…
Loading patent…
AssigneeArgos Therapeutics, Inc.
InventorsIrina Tcherepanova, Aijing Starr, Brad Lackford
Estimating the term…
The invention relates to improved methods and compositions for the nucleic acid amplification of one or multiple variants (strains) of Human Immunodeficiency Virus (HIV) present in a sample, and preferably in a sample from a pathogen infected individual. In particular, novel primers, methods and kits for the amplification of one or more species of HIV Rev, Gag and Nef nucleic acids are provided. The amplified HIV nucleic acid can be used to identify and/or quantitate HIV variants present in a sample. Nucleic acids produced by the methods of the invention or the proteins encoded thereby can also be used directly as vaccines or to transfect/load antigen presenting cells. The loaded antigen presenting cells can be used as a vaccine for the treatment or prevention of HIV infection.
A composition comprising a Gag reverse primer selected from the group consisting of SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48, or any combination thereof.
The composition of claim 12, which comprises the Gag R1833 primers of SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:44.
The composition of claim 12, which comprises Gag R 1884 primers of SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48.
The composition of claim 12, further comprising one or more Gag forward primers selected from the group consisting of SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33.
The composition of claim 15, which comprises:
The composition of claim 15, which comprises:
The composition of claim 15, which comprises:
A method for amplifying an HIV Gag nucleic acid, comprising carrying out a polymerase chain reaction using at least one or a combination of Gag forward primers selected from the group consisting of SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32 and SEQ ID NO:33;
Dependencies are inferred from the claim text.